GE Healthcare to Acquire Cancer Diagnostic Company Clarient Inc.

-- Addition of high-growth business will create strong technology-enabled services platform in molecular diagnostics
-- Complementary capabilities in diagnostics will improve patient care, reduce costs

GE Healthcare, a unit of General Electric Company (NYSE:GE ), and Clarient, Inc. (Nasdaq:CLRT ) announced today that they have entered into a definitive agreement for GE Healthcare to acquire Clarient, a leading player in the fast-growing molecular diagnostics sector.  Clarient's technologies, combined with GE Healthcare's strengths in diagnostic imaging, are expected to accelerate the development of new integrated tools for the diagnosis and characterization of cancer.  A subsidiary of GE will commence a tender offer for all outstanding common and preferred shares of Clarient at $5.00 per common share and $20.00 per preferred share, in each case payable in cash.

Adeona Announces HartLab Expansion Into Microbiology Testing Services

Adeona Pharmaceuticals, Inc. (Amex: AEN) announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, has expanded its in-house diagnostic testing services to include a full array of microbiology testing. Adeona believes that that this expansion of services will be accretive to HartLab's revenues in the current quarter and beyond and is consistent with Adeona's plans to continue to build the revenues of its HartLab subsidiary.

Microbiology testing includes a broad array of tests for the identification and sensitivity testing of the causative agents of infectious diseases followed by prompt, accurate reporting of results. HartLab has the ability to develop and implement new culture techniques, immunoassays, and molecular methods for rapid detection and identification of common as well as unusual microbial pathogens. Serologic testing is also available for confirmation of infections by demonstrating the presence of specific antibody responses.

MedMira Partner Vitest Signs Exclusive Agreement with Red Cross Nigeria to Provide 2 Million Rapid HIV Tests

MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer of rapid diagnostic technology and solutions, today announced that the Company's strategic business development partner for Africa, Vitest AG, has signed an exclusive agreement with the Nigerian Red Cross Society to provide two million MedMira rapid HIV tests under private label. This two million test order is the first part of a broader, long term partnership between Vitest and the Red Cross to enhance public awareness of HIV and testing programs within Nigeria.

"Our exclusive contract with the Red Cross is a milestone in our efforts to create long term partnerships in Africa. The Red Cross in Nigeria has been conducting a rigorous evaluation of the quality, ease of use, and technical support associated with the product over the last six months.

Virtual Radiologic to Be Acquired by Providence Equity Partners

Virtual Radiologic Corporation (NASDAQ: VRAD), a national radiology practice and a leader in the development of radiologist workflow technology, and Providence Equity Partners, a leading global private equity firm that manages over $22 billion in equity capital, today announced that they have entered into a definitive agreement under which Providence will acquire all of the outstanding common stock of vRad for $17.25 per share in cash. The offer price represents a premium of 41.7 percent over the 30-day average closing stock price of $12.18 as of May 14, 2010, and a premium of 54.9 percent over the three month average closing stock price of $11.13. Based on the per share consideration, the transaction is valued at approximately $294 million.